特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
754194

呼吸器疾患治療薬の世界市場:2018年~2022年

Global Respiratory Drugs Market 2018-2022

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 113 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
呼吸器疾患治療薬の世界市場:2018年~2022年
出版日: 2018年11月12日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 113 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

呼吸器疾患管理のコストが高いことから、呼吸器疾患治療薬市場の成長が見込まれています。呼吸器疾患管理のコストが高いことから、Lung Foundation Australiaなどの組織は、費用を削減するために政府からの支援と資金を要請しています。 Technavioのアナリストは、呼吸器疾患治療薬市場が2022年までに約6%のCAGRで成長すると予測しています。

当レポートでは、世界の呼吸器疾患治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第5章 パイプライン分析

  • パイプライン分析

第6章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模および予測(2017年~2022年)

第7章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第8章 市場セグメンテーション:呼吸器疾患の種類別

  • セグメンテーション:呼吸器疾患の種類別(2017年~2022年)
  • 比較:呼吸器疾患の種類別
  • 喘息
  • COPD
  • アレルギー性鼻炎
  • 嚢胞性線維症
  • 特発性肺線維症
  • 他の呼吸器疾患
  • 市場機会:呼吸器疾患の種類別

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション(2017年~2022年)
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

  • 高い呼吸器疾患管理コスト
  • 生物製剤およびバイオシミラーの入手可能性
  • 補完的および代替的医薬品の高い使用
  • ジェネリック医薬品の参入

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis

第16章 付録

  • 略語のリスト
図表
  • Exhibit 01: Parent market: Market size
  • Exhibit 02: Global pharmaceuticals market: Segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs under Phase III development
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global respiratory drugs market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 10: Global respiratory drugs market - Year over year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Global respiratory drugs market by type of respiratory disease - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by type of respiratory disease
  • Exhibit 21: Global respiratory drugs market by asthma - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 22: Global respiratory drugs market by asthma - Year over year growth 2018-2022 (%)
  • Exhibit 23: Global respiratory drugs market by COPD - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 24: Global respiratory drugs market by COPD - Year over year growth 2018-2022 (%)
  • Exhibit 25: Global respiratory drugs market by allergic rhinitis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Global respiratory drugs market by allergic rhinitis - Year over year growth 2018-2022 (%)
  • Exhibit 27: Global respiratory drugs market by cystic fibrosis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 28: Global respiratory drugs market by cystic fibrosis - Year over year growth 2018-2022 (%)
  • Exhibit 29: Global respiratory drugs market by idiopathic pulmonary fibrosis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 30: Global respiratory drugs market by idiopathic pulmonary fibrosis - Year over year growth 2018-2022 (%)
  • Exhibit 31: Global respiratory drugs market by other respiratory disorders - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 32: Global respiratory drugs market by other respiratory disorders - Year over year growth 2018-2022 (%)
  • Exhibit 33: Market opportunity by type of respiratory disease
  • Exhibit 34: Customer landscape
  • Exhibit 35: Global respiratory drugs market by region - Market share 2017-2022 (%)
  • Exhibit 36: Regional comparison
  • Exhibit 37: Respiratory drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 38: Respiratory drugs market in Americas - Year over year growth 2018-2022 (%)
  • Exhibit 39: Top three countries in Americas
  • Exhibit 40: Respiratory drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 41: Respiratory drugs market in EMEA - Year over year growth 2018-2022 (%)
  • Exhibit 42: Top three countries in EMEA
  • Exhibit 43: Respiratory drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 44: Respiratory drugs market in APAC - Year over year growth 2018-2022 (%)
  • Exhibit 45: Top three countries in APAC
  • Exhibit 46: Market opportunity
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AstraZeneca overview
  • Exhibit 53: AstraZeneca - Business segments
  • Exhibit 54: AstraZeneca - Organizational developments
  • Exhibit 55: AstraZeneca - Geographic focus
  • Exhibit 56: AstraZeneca - Key offerings
  • Exhibit 57: GlaxoSmithKline overview
  • Exhibit 58: GlaxoSmithKline - Business segments
  • Exhibit 59: GlaxoSmithKline - Organizational developments
  • Exhibit 60: GlaxoSmithKline - Geographic focus
  • Exhibit 61: GlaxoSmithKline - Segment focus
  • Exhibit 62: GlaxoSmithKline - Key offerings
  • Exhibit 63: Merck overview
  • Exhibit 64: Merck - Business segments
  • Exhibit 65: Merck - Organizational developments
  • Exhibit 66: Merck - Geographic focus
  • Exhibit 67: Merck - Segment focus
  • Exhibit 68: Merck - Key offerings
  • Exhibit 69: Novartis overview
  • Exhibit 70: Novartis - Business segments
  • Exhibit 71: Novartis - Organizational developments
  • Exhibit 72: Novartis - Geographic focus
  • Exhibit 73: Novartis - Segment focus
  • Exhibit 74: Novartis - Key offerings
目次
Product Code: IRTNTR21841

About this market

The high cost of respiratory disease management is expected to drive growth in the respiratory drugs market. The high cost of respiratory disease management has led the organizations such as the Lung Foundation Australia to demand support and funding from the government to reduce the cost. Technavio's analysts have predicted that the respiratory drugs market will register a CAGR of almost 6% by 2022.

Market Overview

Increase in incidence and prevalence of different types of respiratory diseases

Globally, respiratory diseases are a key cause of mortality and disease burden. Numerous types of respiratory diseases are on the rise, thereby pushing growth in the respiratory drugs market.

Patient non-adherence treatment

Non-adherence to treatment is particularly problematic for asthma and COPD disease management due to heterogeneous patient population. Device switching symptoms variability, and comorbidities are responsible for suboptimal adherence rates.

For the detailed list of factors that will drive and challenge the growth of the respiratory drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including AstraZeneca and GlaxoSmithKline, the competitive environment is quite intense. Factors such as the high cost of respiratory disease management and the increase in incidence and prevalence of different types of respiratory diseases, will provide considerable growth opportunities to respiratory drugs manufactures. AstraZeneca, GlaxoSmithKline, Novartis, and Merck are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. Several respiratory drug companies are focused on evolving new respiratory drugs with the entry of biologics and biosimilars for promising options for respiratory disease management.'

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF RESPIRATORY DISEASE

  • Segmentation by type of respiratory disease
  • Comparison by type of respiratory disease
  • Asthma - Market size and forecast 2017-2022
  • COPD - Market size and forecast 2017-2022
  • Allergic rhinitis - Market size and forecast 2017-2022
  • Cystic fibrosis - Market size and forecast 2017-2022
  • Idiopathic pulmonary fibrosis - Market size and forecast 2017-2022
  • Other respiratory disorders - Market size and forecast 2017-2022
  • Market opportunity by type of respiratory disease

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • High cost of respiratory disease management
  • Availability of biologics and biosimilars
  • High use of complementary and alternative medicines
  • Entry of generics

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis

PART 16: APPENDIX

  • List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.